Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Bristol-Myers Squibb Company is a global biopharmaceutical company. The Company develops, licenses, manufactures, markets, and sells pharmaceutical and nutritional products. Bristol-Myers Squibb products and experimental therapies address cancer, heart disease, HIV and AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection, and psychiatric disorders.
Website: bms.com


  • Good financial results growth rate 19.2% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (-6.8%)
  • Dividend yield for the last twelve months 5.3%
  • Free cash flow yield 9.7% (LTM)
  • Share price is 16.8% higher than minimum and 42.9% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (20.4x vs
    )
  • Fundamental value created in LTM (estimate)

Key Financials (Download financials)

Ticker: BMY
Share price, USD:  (0.0%)46.34
year average price 52.60  


year start price 49.74 2024-09-18

max close price 63.11 2025-03-10

min close price 43.31 2025-07-31

current price 46.34 2025-09-17
Common stocks: 2 111 517 922

Dividend Yield:  5.3%
FCF Yield LTM: 9.7%
EV / LTM EBITDA: 20.4x
EV / EBITDA annualized: 19.0x
Last revenue growth (y/y):  +0.6%
Last growth of EBITDA (y/y):  +37.9%
Historical revenue growth:  +0.5%
Historical growth of EBITDA:  -14.2%
Target EV / EBITDA (hist percentile):
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 97 848
Net Debt ($m): 36 640
EV (Enterprise Value): 134 488
EBITDA LTM ($m): 6 595
EV / LTM EBITDA: 20.4x
Price to Book: 5.7x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-09-17reuters.com

Bristol Myers to sell 60% stake in China joint venture

2025-09-09zacks.com

Bristol Myers Squibb (BMY) Outperforms Broader Market: What You Need to Know

2025-09-08benzinga.com

BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy

2025-09-08seekingalpha.com

Bristol-Myers Squibb Company (BMY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

2025-09-08reuters.com

BioNTech, Bristol Myers' immunotherapy shows encouraging tumour shrinkage in Phase II trial

2025-09-07seekingalpha.com

Bristol-Myers Squibb: Growth Portfolio Surpasses Legacy, Driving Oncology And Immunology Leadership

2025-09-06seekingalpha.com

Bristol Myers Squibb: A 5% Yield And Single-Digit P/E Still Look Good

2025-09-05seekingalpha.com

Bristol-Myers Squibb: Buy Before The Market Realizes Its Folly

2025-09-02zacks.com

Will Opdivo and Opdivo Qvantig Drive BMY's Top-Line Growth?

2025-09-01forbes.com

7 Big Yields From The Beat-Up Healthcare Sector
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data